ATE387217T1 - Mannose-6-phosphat rezeptor vermittelter gentransfer zu muskelzellen - Google Patents
Mannose-6-phosphat rezeptor vermittelter gentransfer zu muskelzellenInfo
- Publication number
- ATE387217T1 ATE387217T1 AT03077205T AT03077205T ATE387217T1 AT E387217 T1 ATE387217 T1 AT E387217T1 AT 03077205 T AT03077205 T AT 03077205T AT 03077205 T AT03077205 T AT 03077205T AT E387217 T1 ATE387217 T1 AT E387217T1
- Authority
- AT
- Austria
- Prior art keywords
- mannose
- muscle cells
- phosphate receptor
- gene transfer
- mediated gene
- Prior art date
Links
- 210000000663 muscle cell Anatomy 0.000 title abstract 3
- NBSCHQHZLSJFNQ-QTVWNMPRSA-N D-Mannose-6-phosphate Chemical compound OC1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H](O)[C@@H]1O NBSCHQHZLSJFNQ-QTVWNMPRSA-N 0.000 title 1
- 108090000623 proteins and genes Proteins 0.000 title 1
- 206010013801 Duchenne Muscular Dystrophy Diseases 0.000 abstract 2
- 230000000692 anti-sense effect Effects 0.000 abstract 2
- 229930182470 glycoside Natural products 0.000 abstract 2
- 150000002338 glycosides Chemical class 0.000 abstract 2
- 102000001039 Dystrophin Human genes 0.000 abstract 1
- 108010069091 Dystrophin Proteins 0.000 abstract 1
- 108010031792 IGF Type 2 Receptor Proteins 0.000 abstract 1
- 102000019218 Mannose-6-phosphate receptors Human genes 0.000 abstract 1
- 108091034117 Oligonucleotide Proteins 0.000 abstract 1
- 239000000074 antisense oligonucleotide Substances 0.000 abstract 1
- 238000012230 antisense oligonucleotides Methods 0.000 abstract 1
- 230000015572 biosynthetic process Effects 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 238000001727 in vivo Methods 0.000 abstract 1
- 239000003446 ligand Substances 0.000 abstract 1
- 238000003786 synthesis reaction Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
Landscapes
- Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP03077205A EP1495769B1 (de) | 2003-07-11 | 2003-07-11 | Mannose-6-Phosphat Rezeptor vermittelter Gentransfer zu Muskelzellen |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE387217T1 true ATE387217T1 (de) | 2008-03-15 |
Family
ID=33442814
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT03077205T ATE387217T1 (de) | 2003-07-11 | 2003-07-11 | Mannose-6-phosphat rezeptor vermittelter gentransfer zu muskelzellen |
Country Status (5)
| Country | Link |
|---|---|
| EP (1) | EP1495769B1 (de) |
| AT (1) | ATE387217T1 (de) |
| DE (1) | DE60319354T2 (de) |
| DK (1) | DK1495769T3 (de) |
| ES (1) | ES2302898T3 (de) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK1766010T3 (da) | 2004-06-28 | 2011-06-06 | Univ Western Australia | Antisense-oligonukleotider til induktion af exon-skipping og fremgangsmåder til anvendelse deraf |
| GB0524987D0 (en) | 2005-12-08 | 2006-01-18 | Ge Healthcare Ltd | Novel imaging agents for fibrosis |
| WO2007123391A1 (en) | 2006-04-20 | 2007-11-01 | Academisch Ziekenhuis Leiden | Therapeutic intervention in a genetic disease in an individual by modifying expression of an aberrantly expressed gene. |
| EP1857548A1 (de) | 2006-05-19 | 2007-11-21 | Academisch Ziekenhuis Leiden | Mittel und Verfahren zur Induktion von Exon-skipping |
| WO2008018795A1 (en) | 2006-08-11 | 2008-02-14 | Prosensa Technologies B.V. | Methods and means for treating dna repeat instability associated genetic disorders |
| EP2167136B1 (de) | 2007-07-12 | 2016-04-20 | BioMarin Technologies B.V. | Moleküle für targeting von verbindungen auf verschiedene ausgewählte organe oder gewebe |
| WO2009008725A2 (en) | 2007-07-12 | 2009-01-15 | Prosensa Technologies B.V. | Molecules for targeting compounds to various selected organs, tissues or tumor cells |
| USRE48468E1 (en) | 2007-10-26 | 2021-03-16 | Biomarin Technologies B.V. | Means and methods for counteracting muscle disorders |
| ES2639852T3 (es) | 2007-10-26 | 2017-10-30 | Academisch Ziekenhuis Leiden | Medios y métodos para contrarrestar los trastornos musculares |
| NZ587178A (en) | 2008-02-08 | 2011-11-25 | Prosensa Holding Bv | Methods and means for treating dna repeat instability associated genetic disorders |
| EP2119783A1 (de) | 2008-05-14 | 2009-11-18 | Prosensa Technologies B.V. | Verfahren für effizientes Exon (44)-Skipping bei Duchenne-Muskeldystrophie und entsprechende Mittel |
| IL313162A (en) | 2008-10-24 | 2024-07-01 | Sarepta Therapeutics Inc | Antisense compounds for inducing axon termination and preparations containing them for the treatment of muscular dystrophy |
| JP2012524540A (ja) | 2009-04-24 | 2012-10-18 | プロセンサ テクノロジーズ ビー．ブイ． | Ｄｍｄを処置するためのイノシンを含むオリゴヌクレオチド |
| CA2766614C (en) * | 2009-07-03 | 2018-06-19 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | Compounds targeting the cation-independent mannose 6-phosphate receptor |
| KR20230137491A (ko) | 2009-11-12 | 2023-10-04 | 더 유니버시티 오브 웨스턴 오스트레일리아 | 안티센스 분자 및 이를 이용한 질환 치료방법 |
| AU2010335039B2 (en) | 2009-12-24 | 2015-03-26 | Academisch Ziekenhuis Leiden H.O.D.N. Lumc | Molecule for treating an inflammatory disorder |
| CN118581086A (zh) | 2012-01-27 | 2024-09-03 | 比奥马林技术公司 | 用于治疗杜兴型肌营养不良症和贝克型肌营养不良症的具有改善特性的rna调节性寡核苷酸 |
| EP2908864B1 (de) | 2012-10-22 | 2019-12-11 | Sabag-Rfa Ltd. | Phosphatverbindungen zur abgabe von therapeutika in lebende zellen und zellkerne |
| DK2920307T3 (en) | 2012-11-15 | 2018-07-16 | Roche Innovation Ct Copenhagen As | ANTI-APOB, ANTISENSE CONJUGATE RELATIONSHIPS |
| WO2014118272A1 (en) | 2013-01-30 | 2014-08-07 | Santaris Pharma A/S | Antimir-122 oligonucleotide carbohydrate conjugates |
| DK2951305T3 (en) | 2013-01-30 | 2018-10-29 | Hoffmann La Roche | LNA oligonucleotide KULHYDRATKONJUGATER |
| KR20230116945A (ko) | 2013-03-14 | 2023-08-04 | 사렙타 쎄러퓨틱스 인코퍼레이티드 | 근육 이영양증의 치료를 위한 엑손 스키핑 조성물 |
| KR20150133768A (ko) | 2013-03-15 | 2015-11-30 | 사렙타 쎄러퓨틱스 인코퍼레이티드 | 근육 이영양증의 치료를 위한 개선된 조성물 |
| HUE048738T2 (hu) | 2013-06-27 | 2020-08-28 | Roche Innovation Ct Copenhagen As | Antiszensz oligomerek és konjugátumok, amelyek a PCK9-t célozzák meg |
| GB201408623D0 (en) | 2014-05-15 | 2014-07-02 | Santaris Pharma As | Oligomers and oligomer conjugates |
| CN108779465B (zh) | 2016-03-14 | 2022-05-13 | 豪夫迈·罗氏有限公司 | 用于减少pd-l1表达的寡核苷酸 |
| WO2020173845A1 (en) | 2019-02-26 | 2020-09-03 | Roche Innovation Center Copenhagen A/S | Oligonucleotide formulation method |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6172208B1 (en) * | 1992-07-06 | 2001-01-09 | Genzyme Corporation | Oligonucleotides modified with conjugate groups |
-
2003
- 2003-07-11 EP EP03077205A patent/EP1495769B1/de not_active Expired - Lifetime
- 2003-07-11 AT AT03077205T patent/ATE387217T1/de not_active IP Right Cessation
- 2003-07-11 ES ES03077205T patent/ES2302898T3/es not_active Expired - Lifetime
- 2003-07-11 DE DE60319354T patent/DE60319354T2/de not_active Expired - Lifetime
- 2003-07-11 DK DK03077205T patent/DK1495769T3/da active
Also Published As
| Publication number | Publication date |
|---|---|
| EP1495769B1 (de) | 2008-02-27 |
| DK1495769T3 (da) | 2008-06-23 |
| DE60319354T2 (de) | 2009-03-26 |
| DE60319354D1 (de) | 2008-04-10 |
| EP1495769A1 (de) | 2005-01-12 |
| ES2302898T3 (es) | 2008-08-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE387217T1 (de) | Mannose-6-phosphat rezeptor vermittelter gentransfer zu muskelzellen | |
| Brodyagin et al. | Chemical approaches to discover the full potential of peptide nucleic acids in biomedical applications | |
| EP1191098A3 (de) | Pharmazeutische Zusammensetzung zur Behandlung von Duchenne-Muskeldystrophie | |
| Heemskerk et al. | In vivo comparison of 2′‐O‐methyl phosphorothioate and morpholino antisense oligonucleotides for Duchenne muscular dystrophy exon skipping | |
| EP3284823A3 (de) | Verfahren für effizientes exon-(44)-skipping bei duchenne-muskeldystrophie und zugehörige mittel | |
| EP2500430A3 (de) | Antisense-Oligonukleotide zur Induktion von Exon-Skipping sowie Verfahren zur Verwendung davon | |
| EP2596803A3 (de) | Verfahren zur Zielrichtung von spezifischen Zellpopulationen unter Verwendung von Maytansionoid-Konjugaten mit einem zellbindenden Mittel, verbundenen über einen nichtspaltbaren Linker, besagte Konjugate und Verfahren zur Herstellung der besagten Konjugate | |
| JP2005500025A5 (de) | ||
| EP2487253A3 (de) | Verfahren und Zusammensetzungen auf Mikro-RNA-Basis zur Diagnose und Behandlung von festen Krebsen | |
| IS2957B (is) | Fullmanngerð mótefni gegn 4-1BB (CD137) í mönnum | |
| WO2007125429A3 (en) | Method for the synthesis of triazole- containing oligonucleotide derivatives | |
| EP2135948A3 (de) | ENA-NUKLEINSÄUREARZNEIMITTEL, DIE DAS SPLICING IM mRNA-VORLÄUFER VERÄNDERN | |
| GB0307803D0 (en) | Human genome-derived single exon nucleic acid probes useful for gene expression analysis two | |
| EP2296061A3 (de) | Entwicklerkartusche | |
| EP1485401A4 (de) | Trpm-2-antisense-therapie unter verwendung eines oligonukleotids mit 2 -o-(2-methoxyl)ethylmodifikationen | |
| Rajeev et al. | High-affinity peptide nucleic acid oligomers containing tricyclic cytosine analogues | |
| WO2007072061A3 (en) | Crystalline pyrimidine nucleoside derivatives suspensions in capsules | |
| Lundin et al. | Increased stability and specificity through combined hybridization of peptide nucleic acid (PNA) and locked nucleic acid (LNA) to supercoiled plasmids for PNA-anchored “Bioplex” formation | |
| IL149599A0 (en) | Use of disease-associated gene | |
| Kiviniemi et al. | Synthesis of aminoglycoside-3′-conjugates of 2′-O-methyl oligoribonucleotides and their invasion to a 19F labeled HIV-1 TAR model | |
| WO2000077035A3 (en) | Novel potassium channels and genes encoding these potassium channels | |
| AU2002217893A1 (en) | Universal supports for oligonucleotide synthesis | |
| EP1129725A3 (de) | Oligonukleotid-Konjugate | |
| Kadam et al. | Degradation of phorate by Azotobacter isolates | |
| JP2003508618A5 (de) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |